key: cord-1040268-crfwqcs7
authors: Guaraldi, Giovanni; Milic, Jovana; Martinez, Esteban; Kamarulzaman, Adeeba; Mussini, Cristina; Waters, Laura; Pozniak, Anton; Mallon, Patrick; Rockstroh, Jürgen; Lazarus, Jeffrey V
title: HIV care models during the COVID-19 era
date: 2020-12-19
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1864
sha: 2c56c8333cdff1918b407b2045ae29c1361b6d60
doc_id: 1040268
cord_uid: crfwqcs7

The COVID-19 pandemic is an unprecedented global challenge that substantially risks reversing the progress in ending HIV. At the same time, it may offer the opportunity for a new era of HIV management. This viewpoint presents the impact of COVID-19 on HIV care, including the Joint United Nations Programme on HIV/AIDS (UNAIDS) “three 90s” targets. It outlines how to enhance a patient-centered care approach, now known as the "fourth 90,” by integrating face-to-face patient–physician and telemedicine encounters. It suggests a framework for prevention and treatment of multimorbidity and frailty, to achieve a good health-related quality of life and preserve intrinsic capacity in all people living with HIV.

A c c e p t e d M a n u s c r i p t 4

The COVID-19 pandemic has the potential to alter chronic disease care models and, in particular, usher in a new era of HIV care. HIV is a chronic infectious disease that requires regular care, which is often provided as an in-person (i.e., face to face -F2F) encounter. However, the response to the pandemic has reduced the availability of routine outpatient HIV care. Specifically, many infectious disease physicians have been reassigned to COVID-19 care and many patients have not been able to reach hospitals and clinics due to confinement measures. Communities of people living with HIV (PLHIV) have expressed concern that imposed limitations on clinic visits resulting from COVID-19 and measures to control it may reduce clinical assessments, laboratory procedures, and other clinical services [1] . Further, this has led to suboptimal assessments of the efficacy, toxicity, adherence, and other medication-related aspects of these changes in care [2, 3] . As such, new care models have been considered, including reduced F2F visits [2] , telehealth (ranging from teleconsulting to advanced telemedicine diagnostic and treatment tools) [4] , and the prescription of antiretroviral therapy (ART) for longer periods to ensure uninterrupted supply of medications to the patient's home.

It is not fully understood how COVID-19 affects PLHIV. Epidemiological and clinical reports of COVID-19 outcomes in PLHIV vary according to geographic area. Case-control studies in the European Union (EU) [5] and the United States (US) [6, 7] did not identify differences in COVID-19 severity on admission to hospital or clinical outcomes by HIV status, but showed a higher mortality risk in a recent United Kingdom (UK) study in those under 60 years of age [8] . Nonetheless, a significantly larger proportion of PLHIV had a history of smoking and comorbid illnesses compared to demographically similar HIV-negative patients, which are both risk factors for COVID-19. COVID-19 may also exacerbate the consequences of stigma and discrimination, particularly for the most marginalized populations, including men who have sex with men, people who use drugs, sex workers, transgender people, and people in prisons. All of these populations have been particularly A c c e p t e d M a n u s c r i p t 5 vulnerable to HIV service interruptions during the COVID-19 pandemic [9] . The World Health Organization (WHO) is working with partners, including the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the Global Network of People Living with HIV (GNP+), to safeguard human rights in the response to COVID-19 and allow PLHIV continuous access to HIV-related services (see Table 1 ) [10] . By interrupting HIV treatment services, COVID-19 could hinder progress in HIV care, which may consequently increase morbidity and mortality [11] . Key global HIV/AIDS stakeholders have launched statements and guidelines on HIV management to allow optimal care for PLHIV during the COVID-19 pandemic (see Table 1 ).

In this viewpoint, we outline how to utilize the opportunities afforded by COVID-19 to hasten progress towards patient-centered HIV care, emphasizing the need to recognize and address healthrelated quality of life (HRQoL) in PLHIV.

The contemporary HIV care framework is based on the UNAIDS "90-90-90 targets", which is primarily based on viral-immunological success *12+. The "first 90" target aims to have 90% of PLHIV know their status, which may be compromised due to a reduction in HIV testing as well as prevention efforts, including pre-exposure prophylaxis (PrEP) programs during the pandemic. This may consequently increase the already high proportion of PLHIV with advanced HIV at diagnosis.

Moreover, the risk of stigma related to COVID-19 may drive late presentation among people with respiratory symptoms [13] . However, COVID-19 also offers an opportunity to increase HIV testing in acute medical settings if hospitals establish HIV testing for those suspected or diagnosed with the virus [14] .

The "second 90" target aims to have 90% of those diagnosed with HIV on ART, which is associated with improved survival, decreased HIV-related complications, and reduced HIV transmission. Yet, A c c e p t e d M a n u s c r i p t 6 ART interruption during the pandemic may lead to increased deaths due to HIV. According to one modelling study, deaths could increase by up to 10% compared with pre-pandemic rates in low-/middle-income countries [15] . ART interruption also increases the risk of progression to AIDS, which is especially problematic for patients disengaged in care. Risk factors for progression to AIDS in patients disengaged from care include psychiatric comorbidities, migration status, and alcohol and substance abuse. This highlights the need to identify vulnerable populations, who bear a disproportionate impact of the consequences of the pandemic, and engage them in care, especially since these populations may be less accessible through telemedicine [16] . Therefore, it is crucial to offer personalized and community-based interventions that incorporate re-engagement efforts.

The "third 90 goal" aims to have 90% of people on treatment achieve viral suppression, which could be affected by COVID-19's impact on monitoring frequency. Since the risk of treatment failure on modern ART is low, viral load monitoring, typically every six months, has been postponed for many during the pandemic. It is possible that less frequent monitoring may encourage a shift in consultations to focus on broader issues beyond laboratory results, such as HRQoL. As such, it is necessary to use this COVID-19 "experiment" to develop evidence-based monitoring recommendations.

The management of older PLHIV presenting with multimorbidity and frailty has led to the recognition that viral suppression is not the only endpoint of HIV care, resulting in the development of a "fourth 90" target [17] . The fourth 90 target aims to have 90% of people living with HIV having a good HRQoL. Given that many PLHIV experience multimorbidity and frailty, which may have worsened during the pandemic, medical care should no longer focus primarily on "disease" *18+ but be broadened to an outcome perspective that also addresses quality of life (QoL) and healthy living with HIV. Incorporating patient-reported outcomes (PROs) to routinely assess HRQoL provides a A c c e p t e d M a n u s c r i p t 7 measure of symptom severity and patients' functional and social capacities associated with healthcare or treatment [19] .

HIV care must move beyond viral-immunological success to incorporate patient-centered outcomes based on the intrinsic characteristics of the individual and their environment [20] . Care should take into account the mental and physical health complexes as well as social challenges of each patient to tailor care to their needs. Furthermore, service redesign should be oriented around the diverse needs of individuals, rather than the prerequisites of providers, and must ensure health equity. In particular, any changes to care delivery must address existing disparities in access and care among vulnerable populations to enhance care.

A patient-centered health model could utilize telemedicine, which has been used increasingly during the pandemic and offers new research opportunities and the possibility of redesigning previous models of care. Realizing the promise of telehealth requires an understanding of how telemedicine can contribute to the full care spectrum, including data collection, patient empowerment, diagnosis, and therapy provision. The degree to which telemedicine impacts the provision of evidence-based care, and quality of care, must be assessed in the case of HIV. Nonetheless, telemedicine should not be limited to those providing HIV medical services but should comprise other healthcare professionals involved in HIV care such as nurses, psychologists, pharmacists, and other medical specialists that provide diagnostic and exploratory procedures.

To optimize care delivery, telemedicine should be combined with the traditional F2F patientphysician encounter, which is often considered essential at the time of HIV diagnosis. Following the first F2F encounter at diagnosis, subsequent visits can utilize both F2F and telehealth encounters. Clinical Society (EACS) guidelines [21] . It sets out 13 procedures that require a physical appointment, such as drawing blood, and 13 assessments that could be carried out by telemedicine, such as selfreported anthropometry, drug reconciliation lists, and patient-reported outcomes. Overall, the follow-up time schedule suggests two to three patient-physician encounters each year, alternating one F2F meeting and one or two subsequent telephone/video calls 4-6 months apart. Some health data could be obtained both with telehealth and F2F. The former should not be considered a surrogate of the latter: for instance, self-reported frailty is complementary rather than a substitute for assessment of the frailty phenotype. Similarly, in the context of polypharmacy, a self-collected drug reconciliation list, possibly through dedicated smartphone apps, may be an adequate pre- Future research should aim to investigate the best methods for collecting information on each of the intrinsic capacity domains, including mobility, cognition, psychosocial, sensory, and vitality domains.

Currently, digital biomarkers are already in use for existing health services. These integrate the internet services of medical things, which use innovative healthcare information technology A c c e p t e d M a n u s c r i p t 9 systems, in clinical settings. Predictive medicine in particular is a unique tool for HIV care, which can shift the clinical evaluations of specific diseases to the overall health of the individual. Predictive medicine relies on machine learning to predict observations [24, 25] and offers a unique opportunity for "P4 medicine" (Preventive, Predictive, Personalized, and Participatory), which, if applied to HIV care, may help make it more proactive [25] . Ultimately, such transformations can be utilized alongside telemedicine to maximize wellness for each individual rather than simply treat disease [26] .

This shift towards patient-centered models of care has already started in HIV medicine and the disruption introduced by the COVID-19 pandemic is driving further innovation. Our task is now to provide evidence as to how these changes impact achievement of all four HIV "90" targets.

The COVID-19 crisis is an unprecedented challenge for healthcare systems worldwide. Nevertheless, it offers the opportunity to accelerate a shift towards personalized and people-centered approaches to improve the health of PLHIV. 

This work was not funded. M a n u s c r i p t 

HIV Care in the COVID-19 Era: A Community Perspective In collaboration with the European AIDS Treatment Group (EATG)

EATG Rapid Assessment COVID-19 crisis' Impact on PLHIV and on Communities Most Affected by HIV (Issue 2)

HIV Care Continuum and COVID-19 Outcomes Among People Living with HIV During the COVID-19 Pandemic

Covid-19 and health care's digital revolution

Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort

Clinical Characteristics and Outcomes in People Living With Human Immunodeficiency Virus Hospitalized for Coronavirus Disease

SARS-CoV-2 and HIV coinfection: clinical experience from Rhode Island, United States

Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): a prospective observational study

Q&A: HIV, antiretrovirals and COVID-19

Modelling the extreme-COVID-19 and AIDS-related deaths

An ambitious treatment target to help end the AIDS epidemic

Social stigma in the time of Coronavirus

COVID-19 and HIV: Calling attention to the importance of ensuring HIV status and testing is included in the management of COVID-19

Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study

Comparison of two cohorts of patients presenting with AIDS: Patients with previously known HIV diagnoses and true late presenters

Beyond viral suppression of HIV -the new quality of life frontier

The Burden of COVID-19 in People Living with HIV: A Syndemic Perspective

Cochrane Handbook for Systematic Reviews of Interventions

Quality of life assessment comes of age in the era of highly active antiretroviral therapy

WHO Guidelines on Integrated Care for Older People (ICOPE)

Prediction of treatment response in rheumatoid arthritis patients using genome-wide SNP data

Predictive Analytics for Retention in Care in an Urban HIV

Predictive, personalized, preventive, participatory (P4) cancer medicine

The follow-up time schedule suggests two to three patient-physician encounters each year, alternating one F2F meeting and one or two subsequent telephone/video calls 4-6 months apart.